Key Takeaways
- Fresh comparative data from Eli Lilly demonstrates Foundayo’s superiority over Novo Nordisk’s oral semaglutide for type 2 diabetes management.
- At a 17.2 mg dosage, Foundayo achieved approximately 2% additional weight reduction compared to the 25 mg Ozempic pill.
- The high-dose Ozempic pill remains unapproved in the United States for diabetes treatment, with FDA authorization anticipated before the close of 2026.
- In a separate analysis, Lilly demonstrated that elevated Zepbound doses surpass Novo’s Wegovy HD for weight management.
- Individuals taking Zepbound at 15 mg experienced approximately 5% greater weight reduction versus Wegovy HD recipients.
Eli Lilly has intensified its competitive positioning in the obesity and diabetes treatment market with fresh clinical evidence. The pharmaceutical giant published comparative analyses positioning its therapies against competing products from Novo Nordisk.
This Tuesday, the Indianapolis-based company announced that Foundayo demonstrates superior performance compared to Novo’s oral Ozempic formulation in adults managing type 2 diabetes. These conclusions derive from an indirect statistical comparison rather than a direct clinical trial.
The pharmaceutical company utilized information from two distinct advanced-phase clinical investigations to establish its comparison. Researchers evaluated Foundayo’s 17.2 mg formulation against the 25 mg oral semaglutide tablet from Novo.
Based on Lilly’s findings, Foundayo produced as much as 2% superior weight reduction relative to the higher-strength Ozempic tablet. The analysis additionally revealed marginally improved glycemic management.
Currently, Novo’s 25 mg oral semaglutide formulation lacks FDA approval for type 2 diabetes indication in the United States. Regulatory authorities are projected to render a determination before 2026 concludes.
Novo Nordisk Responds
Novo Nordisk quickly contested the comparative analysis. A company representative informed Reuters that the research concentrated on individuals with type 2 diabetes rather than obesity specifically.
This differentiation carries significant implications. Diabetes patients generally experience reduced weight loss in clinical investigations compared to individuals receiving treatment exclusively for obesity management.
Both oral semaglutide and Foundayo are classified as GLP-1 receptor agonists. These pharmaceutical agents function by modulating glucose metabolism and reducing hunger signals.
Zepbound Versus Wegovy HD
Lilly expanded beyond diabetes comparisons. The corporation simultaneously unveiled additional findings contrasting its injectable Zepbound formulation with Novo’s high-dosage Wegovy product.
This evaluation examined Zepbound at 10 mg and 15 mg strengths versus Wegovy HD throughout a 72-week treatment period. Both medications represent prominent injectable obesity therapeutics.
Individuals receiving Zepbound 15 mg achieved approximately 5% additional average body weight reduction compared with Wegovy HD recipients. The 10 mg dosage group experienced roughly 3% greater weight loss.
According to Lilly’s analysis, participants on the 15 mg formulation demonstrated triple the probability of achieving 20% or greater weight loss relative to Wegovy HD users. Treatment discontinuation rates attributable to adverse reactions remained comparable across all dosage cohorts.
The evidence originated from Lilly’s SURMOUNT-1 investigation and Novo’s STEP UP clinical program. Both research initiatives recruited thousands of overweight and obese participants globally.
Lilly unveiled these results during the European Association for the Study of Diabetes annual conference. Rachel Batterham, serving as Lilly’s senior vice president for medical innovation, acknowledged that direct comparative trials represent the optimal standard, while emphasizing that indirect analyses provide valuable insights when direct comparisons prove unavailable.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
